Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06
  • 2025-05
  • 2025-04
  • KX2-391 dihydrochloride: Dual Src Kinase and Tubulin Inhi...

    2026-02-06

    KX2-391 dihydrochloride: Dual Src Kinase and Tubulin Inhibitor for Oncology and Virology Research

    Executive Summary: KX2-391 dihydrochloride (Tirbanibulin dihydrochloride, CAS No. 1038395-65-1) is a selective small molecule targeting Src kinase and tubulin polymerization through distinct non-ATP-competitive mechanisms (Moore et al., 2024). It demonstrates potent antiproliferative activity in vitro, with IC50 values as low as 23 nM in engineered NIH3T3/c-Src527F cells. Clinical formulations are approved for topical treatment of actinic keratosis, and oral regimens have achieved target plasma concentrations in oncology and anti-HBV studies. KX2-391 also inhibits hepatitis B virus (HBV) transcription and botulinum neurotoxin A (BoNT/A) protease activity at well-defined concentrations. APExBIO supplies research-grade KX2-391 dihydrochloride (SKU A3535), validated for reproducible pathway modulation and compatible with standard cell-based and in vivo protocols (APExBIO product page).

    Biological Rationale

    Src kinase is a non-receptor tyrosine kinase implicated in cancer cell proliferation, survival, motility, and invasion (Moore et al., 2024). Tubulin polymerization is essential for mitotic spindle formation and cell division. Dysregulation of Src and tubulin pathways is a hallmark of oncogenesis and viral replication, including hepatitis B virus (HBV) and human papillomavirus (HPV)–related cancers. KX2-391 dihydrochloride is designed to disrupt both signaling and cytoskeletal dynamics, providing a dual-pronged approach against malignant and virally transformed cells. Additionally, Src pathway inhibition modulates downstream effectors such as MEK, ERK, and apoptosis regulators.

    Mechanism of Action of KX2-391 dihydrochloride

    KX2-391 dihydrochloride acts through two independent molecular mechanisms:

    • Src kinase inhibition: Binds to the substrate-binding site of Src kinase in a non-ATP-competitive manner, suppressing phosphorylation and downstream oncogenic signaling (Moore et al., 2024).
    • Tubulin polymerization inhibition: Interacts with a novel site on the α-β tubulin heterodimer, preventing microtubule assembly required for mitosis (KX2-391 Dihydrochloride: Dual Src Kinase and Tubulin Inhibitor). This mechanism is distinct from taxanes or vinca alkaloids.
    • HBV transcription suppression: Targets the HBV precore promoter, downregulating viral RNA synthesis.
    • BoNT/A protease inhibition: Directly interacts with the BoNT/A light chain, blocking SNAP-25 cleavage at micromolar concentrations.

    Evidence & Benchmarks

    • KX2-391 dihydrochloride (Tirbanibulin 1% ointment) is approved in the US/EU for actinic keratosis and achieves clinical lesion resolution in HPV-positive SCC and HGSIL (Moore et al., 2024).
    • IC50 for antiproliferative activity in HeLa cells (HPV-18+): 31.49 nM (24 h, serum-supplemented, 37°C) (Moore et al., 2024).
    • Src kinase pathway proteins (Src, phospho-Src, Ras, c-Raf, ERK1/2) are downregulated in a dose-dependent manner; apoptosis markers (cPARP) are upregulated (Moore et al., 2024).
    • Inhibits Src kinase with IC50 values of 23 nM (NIH3T3/c-Src527F) and 39 nM (SYF/c-Src527F), and tubulin polymerization at ≥80 nM in vitro (KX2-391 Dihydrochloride: Dual Src Kinase and Tubulin Inhibitor).
    • Suppresses HBV transcription with EC50 of 0.14 μM (PXB cells) and 2.7 μM (HepG2-NTCP cells) (KX2-391 Dihydrochloride: Dual Src Kinase and Tubulin Inhibitor).
    • Oral dosing in mice (5–15 mg/kg) and chimpanzees (1 mg/kg, BID) achieves effective plasma concentrations with no significant peripheral neuropathy (APExBIO product page).
    • Typical in vitro working concentrations: 0.013–10 μM for antiproliferative/anti-HBV, 10–40 μM for anti-BoNT/A assays (APExBIO product page).

    Applications, Limits & Misconceptions

    KX2-391 dihydrochloride is utilized in oncology, virology, and neurobiology workflows. Its dual mechanism allows for precise dissection of Src kinase signaling, tubulin polymerization, and HBV replication pathways. Clinically, topical tirbanibulin ointment is approved for actinic keratosis (Moore et al., 2024), while oral regimens are being explored for advanced tumors and viral hepatitis.

    For in vitro research, KX2-391 enables high-sensitivity cell viability and cytotoxicity assays (KX2-391 dihydrochloride: Scenario-Driven Solutions). This article extends the scenario-driven protocols by providing updated clinical benchmarks and pathway-specific data not covered in the referenced guide.

    For an in-depth analysis of pathway selectivity and mechanistic insights, see KX2-391 Dihydrochloride: Pathway-Selective Inhibition — this article updates the translational relevance with recent clinical and anti-HBV data.

    Common Pitfalls or Misconceptions

    • Not effective in water-based buffers: KX2-391 dihydrochloride is insoluble in water; use DMSO or ethanol as recommended vehicles (APExBIO product page).
    • Not a general tubulin inhibitor: Its tubulin binding site is novel and distinct from taxanes/vinca alkaloids; do not substitute for these agents in standard protocols.
    • Not ATP-competitive: Src kinase inhibition is non-ATP-competitive; do not interpret data as classical ATP-site blockade.
    • Not suitable for chronic systemic dosing without validation: Most clinical experience is topical or short-term oral dosing; long-term systemic effects are not fully characterized.
    • Not universally antiviral: Activity is validated for HBV transcription inhibition, not for all viruses.

    Workflow Integration & Parameters

    • Solubility: ≥25.2 mg/mL in DMSO, ≥48.8 mg/mL in ethanol (gentle warming), insoluble in water.
    • Storage: Solid at -20°C. Solutions are for short-term use only.
    • In vitro concentrations: 0.013–10 μM for cancer/anti-HBV; 10–40 μM for anti-BoNT/A.
    • In vivo dosing: Mice: 5–15 mg/kg PO QD/BID; Chimpanzee (anti-HBV): 1 mg/kg BID; human oral: 40–120 mg/day; topical: 1% ointment once daily x5 days.
    • Peak plasma (oral, human): 61–218 ng/mL; minimum effective (anti-HBV): ≥560 nM (241.92 ng/mL).
    • Supplier validation: APExBIO (SKU A3535) provides research-grade KX2-391 dihydrochloride with batch-to-batch consistency (APExBIO product page).

    Conclusion & Outlook

    KX2-391 dihydrochloride is a rigorously characterized, dual-mechanism inhibitor of Src kinase and tubulin polymerization with demonstrated efficacy in cell and animal models of cancer and HBV infection (Moore et al., 2024). Its pathway selectivity and clinical tolerability distinguish it from traditional cytotoxic agents. Future research may expand its translational applications, particularly in HPV- and HBV-associated malignancies and neurotoxin inhibition. For validated, reproducible results, researchers are advised to source KX2-391 dihydrochloride from APExBIO and adhere to recommended protocols. For further protocol guidance and scenario-based application tips, see this detailed workflow article, which this review updates with the latest clinical and mechanistic insights.